ADMA Biologics, Inc. NGM · ADMA
Price alert —
Sign in to get a one-time email the moment ADMA crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · ADMA
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $0.1B | $0.0B | $0.1B | $0.1B | 39.6% | 43.9% |
| 2025-12-31 | $0.1B | $0.0B | $0.1B | $0.0B | 35.5% | 45.1% |
| 2025-09-30 | $0.1B | $0.0B | $0.1B | $-0.0B | 27.1% | 38.0% |
| 2025-06-30 | $0.1B | $0.0B | $0.0B | $0.0B | 28.1% | 35.1% |
| 2025-03-31 | $0.1B | $0.0B | $0.0B | $-0.0B | 23.4% | 30.4% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare ADMA vs peers
Line ADMA up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with ADMA
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-05-06 | 0.17 | 0.20 | -15.2% | -16.0% |
| 2026-02-25 | 0.22 | 0.20 | +7.8% | -3.2% |
| 2025-11-05 | 0.16 | 0.16 | +2.6% | -8.7% |
| 2025-08-06 | 0.14 | 0.14 | +7.4% | -9.7% |
| 2025-05-07 | 0.11 | 0.17 | -33.3% | -10.2% |
| 2025-03-03 | 0.14 | 0.15 | -9.3% | +7.5% |
| 2024-11-07 | 0.15 | 0.13 | +15.4% | +14.7% |
| 2024-08-08 | 0.13 | 0.08 | +62.5% | +30.9% |
| 2024-05-09 | 0.08 | 0.05 | +60.0% | +27.1% |
| 2024-02-28 | 0.04 | 0.02 | +153.3% | -0.4% |
| 2023-11-08 | 0.01 | -0.01 | +200.0% | +5.8% |
| 2023-08-09 | -0.02 | -0.02 | +35.3% | +6.2% |
| 2023-05-10 | -0.03 | -0.04 | +29.4% | +10.9% |
| 2023-03-23 | -0.06 | -0.07 | +18.2% | +6.8% |
| 2022-11-09 | -0.08 | -0.07 | -9.1% | +27.5% |
| 2022-08-10 | -0.07 | -0.08 | +12.5% | +5.2% |
| 2022-05-11 | -0.09 | -0.08 | -8.7% | +17.5% |
| 2022-03-24 | -0.07 | -0.09 | +25.0% | +8.7% |
| 2021-11-10 | -0.13 | -0.14 | +8.4% | +13.6% |
| 2021-08-11 | -0.14 | -0.15 | +8.3% | -1.3% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| ADMA ★ | $2B | 12.3 | 8.5 | 3.8 | 203.4 | 5.0 | 61.3% | 15.9% | — | 3.00% |
| LLY | $1,037B | 41.3 | 25.9 | — | 29.7 | 33.3 | 82.8% | 55.5% | 169.9% | 0.88% |
| UNH | $392B | 32.5 | 19.2 | 0.9 | 17.9 | 3.7 | 19.5% | 0.4% | 61.5% | 5.81% |
| JNJ | $615B | 29.7 | 19.9 | 6.3 | 18.6 | 7.6 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 35.6 | 13.2 | — | 12.1 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $448B | 123.6 | 15.6 | 7.1 | 17.1 | -67.2 | 72.0% | 12.4% | -46.2% | 4.65% |
| PFE | $141B | 18.9 | 8.8 | — | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.75% |
| TMO | $196B | 28.9 | 19.3 | — | 20.9 | 3.8 | 40.9% | 6.2% | 11.3% | 2.82% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 46.96%
| Holder | Shares | % out |
|---|---|---|
| Blackrock Inc. | 36,830,774 | 15.89% |
| State Street Corporation | 14,084,205 | 6.08% |
| Capital Research Global Investors | 11,191,116 | 4.83% |
| Vanguard Capital Management LLC | 10,306,871 | 4.45% |
| Vanguard Portfolio Management LLC | 8,868,657 | 3.83% |
| Nuveen, LLC | 6,098,225 | 2.63% |
| Geode Capital Management, LLC | 5,824,116 | 2.51% |
| Citadel Advisors Llc | 5,810,642 | 2.51% |
| Dimensional Fund Advisors LP | 5,005,481 | 2.16% |
| American Century Companies Inc | 4,789,011 | 2.07% |
Insider activity · 90d
3 buys / 0 sells · ratio 3.0 · Finnhub
- Grossman Jerrold B BUY 520,284 @ $7.91
- Grossman Jerrold B BUY 513,884 @ $8.01
- Grossman Jerrold B BUY 501,384 @ $8.01
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-07-17 | FORM 4 | view · |
| 8-K | 2026-06-02 | 8-K | view · |
| 4 | 2026-05-28 | FORM 4 | view · |
| 4 | 2026-05-14 | FORM 4 | view · |
| 4 | 2026-05-12 | FORM 4 | view · |
| 10-Q | 2026-05-06 | 10-Q | view · |
| 8-K | 2026-05-06 | 8-K | view · |
| 8-K | 2026-05-04 | 8-K | view · |
| DEF 14A | 2026-04-15 | DEF 14A | view · |
| 4 | 2026-04-03 | FORM 4 | view · |
| 8-K | 2026-03-27 | 8-K | view · |
| 4 | 2026-03-17 | FORM 4 | view · |
| 4 | 2026-03-17 | FROM 4 | view · |
| 4 | 2026-03-10 | FORM 4 | view · |
| 4 | 2026-03-10 | FORM 4 | view · |
| 4 | 2026-03-09 | FORM 4 | view · |
| 4 | 2026-03-02 | FORM 4 | view · |
| 8-K | 2026-03-02 | 8-K | view · |
| 10-K | 2026-02-25 | 10-K | view · |
| 8-K | 2026-02-25 | 8-K | view · |
| 4 | 2026-02-23 | FORM 4 | view · |
| 4 | 2026-02-23 | FORM 4 | view · |
| 4 | 2026-02-23 | FORM 4 | view · |
| 4 | 2026-02-17 | FORM 4 | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 4 | 2026-02-11 | FORM 4 | view · |
| 8-K | 2026-01-12 | 8-K | view · |
| 4 | 2025-12-16 | FORM 4 | view · |
| 4 | 2025-11-21 | FORM 4 | view · |
| 10-Q | 2025-11-05 | 10-Q | view · |
| 8-K | 2025-11-05 | 8-K | view · |
| 4 | 2025-10-24 | FORM 4 | view · |
| 4 | 2025-09-16 | FORM 4 | view · |
| 4 | 2025-08-15 | FORM 4 | view · |
| 10-Q | 2025-08-06 | 10-Q | view · |
| 8-K | 2025-08-06 | 8-K | view · |
| 4 | 2025-08-01 | FORM 4 | view · |
| 4 | 2025-07-28 | FORM 4 | view · |
| 4 | 2025-07-28 | FORM 4 | view · |
| 4 | 2025-07-16 | FORM 4 | view · |
| 4 | 2025-06-30 | FORM 4 | view · |
| 4 | 2025-06-18 | FORM 4 | view · |
| 4 | 2025-06-16 | FORM 4 | view · |
| 4 | 2025-06-11 | FORM 4 | view · |
| 4 | 2025-06-10 | FORM 4 | view · |
| 8-K | 2025-06-04 | 8-K | view · |
| 4 | 2025-05-23 | FORM 4 | view · |
| 4 | 2025-05-16 | FORM 4 | view · |
| 10-Q | 2025-05-07 | 10-Q | view · |
| 8-K | 2025-05-07 | 8-K | view · |
| 8-K | 2025-04-28 | 8-K | view · |
| 4 | 2025-04-16 | FORM 4 | view · |
| DEF 14A | 2025-04-15 | DEF 14A | view · |
| 4 | 2025-04-02 | FORM 4 | view · |
About ADMA
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Options picks · ADMA
ITM + OTM ideas from the latest scanLoading…
Congress trades · ADMA
STOCK Act disclosuresLoading…
SEC filings & insiders · ADMA
EDGAR · liveLoading…
Holders · ADMA
Institutions & insider activityLoading…